GANX Stock Summary and Trading Ideas (Gain Therapeutics | NASDAQ:GANX)

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Gain Therapeutics trades on the NASDAQ stock market under the symbol GANX.

As of September 11, 2026, GANX stock price climbed to $1.75 with 206,890 million shares trading.

GANX has a beta of 1.75, meaning it tends to be more sensitive to market movements. GANX has a correlation of 0.05 to the broad based SPY ETF.

GANX has a market cap of $76.38 million. This is considered a Micro Cap stock.

In the last 3 years, GANX traded as high as $5.33 and as low as $.89.

The top ETF exchange traded funds that GANX belongs to (by Net Assets): VXF, BUSM.

GANX has underperformed the market in the last year with a price return of +1.7% while the SPY ETF gained +17.4%. GANX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.6% and -1.1%, respectively, while the SPY returned +3.9% and -0.7%, respectively.

GANX support price is $1.64 and resistance is $1.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GANX shares will trade within this expected range on the day.